Thermo Fisher Scientific (TMO) – Reuters
-
Thermo Fisher forecasts 2024 below estimates, cautious on biotech demand
-
Thermo Fisher's warning on more pain from biotech funding squeeze hits sector
-
Thermo Fisher Scientific to buy Olink in $3.1 billion deal
-
Thermo Fisher to buy diagnostics firm Binding Site for $2.6 billion
-
EU antitrust decision on Thermo Fisher's PPD deal due by Dec. 7
-
Thermo Fisher lifts annual forecast on boost from COVID-related sales
-
Thermo Fisher set to benefit from demand for testing kits, vaccines
-
Thermo Fisher cuts 2021 COVID-19 test sales forecast by $900 million, citing lower demand
-
Thermo Fisher to work with Pfizer-BioNtech on vaccine production in Italy
-
U.S. states race to buy ultra cold vaccine freezers, fueling supply worries
-
Qiagen chairman quits after Thermo Fisher's takeover bid fails
-
Thermo Fisher's Qiagen bid fails after target gets COVID testing boost
-
Davidson Kempner says again it will not be tendering Qiagen shares
-
Qiagen investor Davidson Kempner ups stake to 8%
-
Germany's Qiagen starts shipping coronavirus diagnostic tests to United States
-
Wall Street ticks higher, but chip stocks tumble
-
Thermo Fisher in talks to buy Patheon: Bloomberg
-
Global stocks retreat after Trump tax plan; Canada dollar, Mexico peso weaken
Back to TMO Stock Lookup
